Association between baseline demographic characteristics, clinical data and laboratory values with methotrexate-related adverse events
| Unadjusted OR (95% CI) | p Value | Adjusted OR (95%CI) | p Value | |
|---|---|---|---|---|
| Age (years) | 1.001 (0.97 to 1.03) | 0.961 | 0.997 (0.97 to 1.03) | 0.842 |
| Gender (female vs male) | 1.228 (0.49 to 3.07) | 0.660 | 1.250 (0.49 to 3.17) | 0.639 |
| BMI (kg/m2) | 1.074 (0.96 to 1.20) | 0.197 | 1.076 (0.95 to 1.21) | 0.236 |
| Swollen joint count (number) | 0.956 (0.89 to 1.03) | 0.250 | 0.956 (0.89 to 1.03) | 0.250 |
| Tender joint count (number) | 0.991 (0.93 to 1.06) | 0.779 | 0.986 (0.93 to 1.05) | 0.677 |
| VAS pain (mm) | 1.012 (1.00 to 1.03) | 0.172 | 1.007 (0.99 to 1.03) | 0.398 |
| VAS general well-being (mm) | 1.011 (0.99 to 1.03) | 0.247 | 1.010 (0.99 to 1.03) | 0.327 |
| Functional disability (HAQ) | 1.316 (0.66 to 2.62) | 0.433 | 1.138 (0.54 to 2.38) | 0.732 |
| ESR (mm/h) | 0.987 (0.97 to 1.01) | 0.191 | 0.987 (0.97 to 1.01) | 0.193 |
| Creatinine (µmol/l) | 1.013 (0.98 to 1.05) | 0.444 | 1.008 (0.98 to 1.04) | 0.644 |
| Creatinine clearance (ml/min) | 0.999 (0.98 to 1.02) | 0.953 | 1.002 (0.98 to 1.02) | 0.872 |
| AST (U/l) | 0.992 (0.94 to 1.05) | 0.765 | 0.992 (0.94 to 1.05) | 0.761 |
| ALT (U/l) | 1.008 (0.98 to 1.04) | 0.607 | 0.999 (0.97 to 1.03) | 0.959 |
| Rheumatoid factor status (positive vs negative) | 2.263 (0.73 to 6.99) | 0.156 | 2.464 (0.77 to 7.89) | 0.129 |
Unadjusted and adjusted odds ratios (OR) (adjusted for treatment arm and NSAID use at baseline).
ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase; BMI, body mass index, ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire (0–3, most functional disability); NSAID, non-steroidal anti-inflammatory drug; VAS, visual analogue scale pain and general wellbeing (range 0–100 mm, worst score).